Application of therapeutic drug monitoring of imatinib for individual treatment of gastrointestinal stromal tumor
<p>Many molecular target agents are continuously administered at fixed dosages. Imatinib, which can control the growth of a gastrointestinal stromal tumor, is administrated at 400 mg/day. However, many patients cannot continue treatment because of adverse events, such as neutropenia. To obtain...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IJCTO
2016-06-01
|
| Series: | International Journal of Cancer Therapy and Oncology |
| Subjects: | |
| Online Access: | http://ijcto.org/index.php/IJCTO/article/view/512 |